TransCode Therapeutics is a rising RNA oncology organization, established based on the conviction that overcoming cancer can be achieved through the strategic development and efficient delivery of RNA therapies. We have formulated a range of potential medication with the aim of targeting various types of tumors to enhance patient outcomes. Our primary therapeutic candidate, TTX-MC138, is dedicated to addressing metastatic cancer, which is accountable for about 90% of all cancer fatalities, amounting to over 9 million deaths annually globally. We are optimistic about the potential of TTX-MC138 to induce regression without relapse.